Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer

Figures & data

Table 1. Performance and technical data of the NIPRO 130G and FX60 dialyzers.

Performance data	NIPRO 130G	FX60
KUF, mL/h/mmHg	15.3	46
KoA urea, mL/min	252	276
Creatinine, mL/min	175	182
BUN, mL/min	188	193
Phosphate, mL/min	160	177
Vitamin B12, mL/min	108	135
Technical data
Sterilization mode	γ-ray	Inline steam
Volume, mL	75	74
Membrane material	Triacetyl cellulose	Modified polysulfon (helixone, high-flux)
Wall, μm	40	35
Fiber lumen, μm	200	185
Effective surface area, m^2	1.3	1.4

Clearance for NIPRO 130G and FX 60 at QB = 200 mL/min. Data are based on Fresenius Medical Cares instructions and European standards for hemodialyzers, hemodiafilters, hemofilters, hemoconcentrators and associated blood-tubing systems. KUF, the ultrafiltration coefficient of a dialyzer, ml/h/mmHg; KoA urea, calculated dialyzer mass transfer area coefficient for urea, mL/min.

Table 2. Demographic, clinical and biochemical data of the 30 patients undergoing MHD.

Variable	Value
Age, years	54.1 ± 11.4
Male/female	23/7
Duration of hemodialysis, years	4.8 ± 1.8
Diabetes (%)	6 (20)
Hypertension (%)	19 (63.3)
Cardiocerebrovascular disease (%)	9 (30)
Systolic blood pressure, mmHg	147.1 ± 21.0
Diastolic blood pressure, mmHg	87.0 ± 4.1
Serum creatinine, μmol/L	1229 ± 111.7
Serum albumin, g/L	38.8 ± 4.6
Triglycerides, mmol/L	1.63 ± 0.95
Total cholesterol, mmol/L	4.12 ± 2.60
High-density lipoprotein, mmol/L	0.94 ± 0.12
Low-density lipoprotein, mmol/L	1.82 ± 0.56
Corrected serum calcium, mg/dL	8.7 ± 0.9
Serum phosphorus, mmol/L	1.80 ± 0.50
Calcium phosphate product, mg^2/dL^2	53.2 ± 15.3
iPTH, pg/mL	450.6 ± 650.2
Kt/V	1.41 ± 0.33
Hemoglobin, g/L	108.6 ± 14.9
EPO supplement, IU/week	8632 ± 1908.3

Figures are either mean ± SD or numbers with percentage in parentheses.

Table 3. Comparison of clinical data for one FX60 dialysis and one NIPRO 130G dialysis (n = 30, means ± SD).

Variable	Serum P, mmol/L	Scr, μmol/L	BUN, mmol/L	β2-MG, mg/L	NT-proBNP, pg/mL
Pre-FX60 HD	1.90 ± 0.46	1031.5 ± 164.2	29.8 ± 5.14	40.8 ± 4.2	6934 ± 7821
Post-FX60 HD	0.92 ± 0.20*	411.3 ± 137.2*	10.1 ± 2.23*	26.5 ± 3.5*	5268 ± 4276*
Clearance (%)	49.2 ± 11.0	63.1 ± 6.9	69.5 ± 5.8	35.9 ± 3.8	29.6 ± 3.2
p	0.021	0.007	0.009	0.025	0.045
Pre-NIPRO130G HD	1.81 ± 0.51	1037 ± 157.0	29.5 ± 4.94	42.6 ± 4.5	8135 ± 7351
Post-NIPRO130G HD	0.93 ± 0.38*	418.2 ± 117.1*	10.8 ± 2.12*	40.8 ± 4.8	7853 ± 6613
Clearance (%)	48.1 ± 17.9	63.7 ± 4.5	68.1 ± 4.8	4.8 ± 1.0	2.1 ± 2.2
p	0.031	0.008	0.008	0.363	0.765

*Pre-HD dialysis compared with post-HD dialysis p < 0.05.

P, phosphorus; SCr, serum creatinine; BUN, blood urea nitrogen; β₂-MG, β2-microglobulin; NT-proBNP, amino terminal B-type natriuretic peptide.

Table 4. Comparison of clinical data for patients undergoing pre-LFHD (NIPRO 130G dialyzer) and post-LFHD after two years (n = 30, mean ± SD).

Variable	Pre-LFHD	Post-LFHD	p
TP, g/L	69.6 ± 5.4	72.3 ± 6.1	0.115
Alb, g/L	38.8 ± 4.6	38.6 ± 2.2	0.803
Hb, g/L	108.6 ± 14.9	103.9 ± 18.1	0.386
TC, mmol/L	4.12 ± 2.60	3.83 ± 0.80	0.08
TG, mmol/L	1.63 ± 0.95	1.95 ± 0.99	0.404
HDL, mmol/L	0.94 ± 0.12	0.91 ± 0.27	0.752
LDL, mmol/L	1.82 ± 0.56	2.03 ± 0.55	0.523
P, mmol/L	1.80 ± 0.50	1.93 ± 0.48	0.345
SCr, μmol/L	1229 ± 111.7	1027 ± 147.0	0.354
BUN, mmol/L	28.6 ± 6.1	29.4 ± 4.9	0.605
Corrected serum Ca, mg/dL	8.7 ± 0.9	8.8 ± 0.6	0.604
iPTH, pg/mL	450.6 ± 650.2	525.2 ± 695.6	0.713
Kt/V	1.41 ± 0.33	1.42 ± 0.25	0.226
SF, ng/mL	600.3 ± 297.2	573.6 ± 314.2	0.464
TSAT (%)	36.1 ± 11.4	40.3 ± 15.7	0.229
β2-MG, mg/L	42.7 ± 4.6	40.6 ± 4.5	0.363
SBP, mmHg	147.1 ± 21.0	146.0 ± 12.6	0.267
DBP, mmHg	87.0 ± 4.1	86.2 ± 7.3	0.431
MAP, mmHg	105.2 ± 8.6	106.1 ± 7.4	0.462
UF, kg	3.39 ± 0.38	3.30 ± 0.65	0.351
DWT, Kg	70.9 ± 115	71.5 ± 11.8	0.601
Vit D3, μg/w	2.98 ± 1.87	2.22 ± 1.85	0.789
EPO, IU/w	8632 ± 1908.3	7913.5 ± 3531.2	0.659
Iv Fe, mg/w	55.0 ± 33.4	51.0 ± 30.4	0.64
Anti-hypertensive drugs (DDD)	1.76 ± 1.57	1.78 ± 1.67	0.976

*Pre-LFHD compared with post-LFHD p < 0.05.

HD, hemodialysis; UF, ultrafiltration (Kg); DWT, dry weights (Kg); TSAT, transferrin saturation index (iron/TIBC); SF, serum ferritin; SBP, systolic blood pressure; DBP, diastolic blood pressure; CaP, calcium phosphate product; TC, total cholesterol; TG, triglyceride; P, serum phosphorus; Alb, serum albumin; SCr, serum creatinine; BUN, blood urea nitrogen; HDL, high density lipoprotein; LDL, low density lipoprotein; iPTH, intact parathyroid hormone; β₂-MG, β2-microglobulin; EPO, erythropoietin (u/w); Iv Fe intravenous ferrous (mg/w); MAP, mean arterial pressure.

Table 5. Comparison of clinical data for patients undergoing pre-HFHD (FX60 dialyzer) and after one-year HFHD or three-years HFHD (mean ± SD).

Variable	Pre-HFHD	Post-HFHD1	Post-HFHD3	P1	P3
Male/Female	23/7	23/7	20/5
TP, g/L	72.3 ± 6.1	71.3 ± 4.4	69.5 ± 3.8	0.239	0.315
Alb, g/L	38.6 ± 2.2	39.3 ± 1.6	40.6 ± 1.7^#	0.522	0.032
Hb, g/L	103.9 ± 18.1	111.8 ± 11.5*	115.8 ± 7.8^#	0.013	0.011
TC, mmol/L	3.83 ± 0.80	3.64 ± 0.93	4.01 ± 0.73	0.111	0.091
TG, mmol/L	1.95 ± 0.99	1.72 ± 0.61	1.88 ± 1.11	0.291	0.304
HDL, mmol/L	0.91 ± 0.27	0.92 ± 0.28	0.95 ± 0.23	0.337	0.352
LDL, mmol/L	2.03 ± 0.55	2.02 ± 0.57	2.01 ± 0.55	0.523	0.533
P, mmol/L	1.93 ± 0.48	1.70 ± 0.21*	1.65 ± 0.39^#	0.047	0.035
SCr, μmol/L	1027 ± 147.0	1025 ± 161.6	1100 ± 227.3	0.905	0.864
BUN, mmol/L	29.4 ± 4.9	29.9 ± 5.1	28.1 ± 4.4	0.395	0.405
Corrected serum Ca, mg/dL	8.8 ± 0.6	8.9 ± 0.4	8.7 ± 0.4	0.829	0.704
CaP, mg^2/dL^2	53.2 ± 15.3	51.2 ± 11.7	45.4 ± 12.2^#	0.271	0.034
iPTH, pg/mL	525.2 ± 695.6	437.3 ± 417.2*	237.8 ± 174.3^#	0.046	0.023
Kt/V	1.42 ± 0.25	1.45 ± 0.39	1.48 ± 0.19	0.215	0.236
SF, ng/mL	573.6 ± 314.2	536.0 ± 290.7	528.4 ± 219.8	0.061	0.060
TSAT (%)	40.3 ± 15.7	35.3 ± 17.4	26.5 ± 6.4^#	0.064	0.039
NT-proBNP, pg/mL	7933 ± 6531	6724 ± 8721*	5274 ± 5612^#	0.035	0.028
β2-MG, mg/L	40.6 ± 4.5	33.5 ± 3.3*	32.6 ± 3.6^#	0.032	0.030
SBP, mmHg	146.0 ± 12.6	142.5 ± 10.1	147.2 ± 14.1	0.067	0.367
DBP, mmHg	86.2 ± 7.3	84.1 ± 6.1*	82.7 ± 6.7^#	0.043	0.031
MAP, mmHg	106.1 ± 7.4	104.5 ± 7.3*	102.4 ± 7.0^#	0.042	0.032
UF, kg	3.30 ± 0.65	3.29 ± 0.69	3.09 ± 0.59	0.667	0.650
DWT, Kg	71.5 ± 11.8	71.5 ± 12.1	70.5 ± 12.4	0.561	0.519
LVEF, %	60.0 ± 7.3	64.2 ± 8.7*	66.2 ± 5.4^#	0.040	0.030
Vit D3, μg/w	2.22 ± 1.85	2.12 ± 1.61	1.96 ± 1.51^#	0.708	0.042
EPO, IU/w	7913.5 ± 3531.2	7490.4 ± 3933.5	7840.9 ± 3132.8	0.332	0.631
Iv Fe, mg/w	51.0 ± 30.4	47.6 ± 29.8	59.1 ± 34.0	0.618	0.340
Anti-hypertensive drugs (DDD)	1.78 ± 1.67	1.58 ± 1.50	1.01 ± 0.86^#	0.381	0.036

* p < 0.05, P1 is post-HFHD1 compared with pre-HFHD, P3 is post-HFHD3 compared with pre-HFHD. Post-HFHD1 is after one year of HFHD, post-HFHD3 is after three years of HFHD.

HD, hemodialysis; UF, ultrafiltration (Kg); DWT, dry weights (Kg); TSAT, transferrin saturation index (iron/TIBC); SF, serum ferritin; SBP, systolic blood pressure; DBP, diastolic blood pressure; CaP, calcium phosphate product; TC, total cholesterol; TG, triglyceride; P, serum phosphorus; Alb, serum albumin; SCr, serum creatinine; BUN, blood urea nitrogen; HDL, high density lipoprotein; LDL, low density lipoprotein; iPTH, intact parathyroid hormone; β₂-MG, β2-microglobulin; EPO, erythropoietin (u/w); Iv Fe intravenous ferrous (mg/w); MAP, mean arterial pressure; LVEF, left ventricular ejection fraction.